Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
(RS)-APICACat. No. 1073 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: (RS)-1-Amino-5-phosphonoindan-1-carboxylic acid |
Biological Activity
Rigidified analog of MPPG (Cat. No. 0853); selective group II metabotropic glutamate receptor antagonist (IC50 = 30 μM) with no significant effect on group I and III mGlu receptors at concentrations up to 1 mM. Increases extracellular glutamate concentrations and possesses unusual inverse agonist-like action.Technical Data
M.Wt:The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Ma et al (1997) Synthesis and biological activity of cyclic analogues of MPPG and MCPG as metabotropic glutamate receptor antagonists. Bioorg.Med.Chem.Lett. 7 1195.
Krenz et al (2000) Group I, II and III mGluR compounds affect rhythm generation in the gastric circuit of the crustacean stomatogastric ganglion. J.Neurophysiol. 83 1188. PMID: 10712449.
Xi et al (2002) Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J.Pharmacol.Exp.Ther. 300 162. PMID: 11752112.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: (RS)-APICA, supplier, Selective, group, II, antagonists, mGlur, Group, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic
Quick Order
Find multiple products by catalog number
Pain Research Product Guide
Highlights over 280 products for Pain research. Request copy or view PDF today.
mGlu Receptors Review
Written by Francine Acher, an expert in the field. Request a copy or view PDF today.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
New Products in this Area
Selective negative allosteric modulator of group II mGlu receptors
VU 0285683Negative allosteric modulator at mGlu5
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.